

FLO^RIDA X^TIMES



In This Issue

- Message from the President
- Clinical Pearl Article
- Special Insights
- FSHP Component Welcome!
- Regional Society Updates
- Student Chapter Updates
- 2025 FSHP Awards & Scholarship Winners
- FSHP Annual Meeting Recap

How are we doing
with the newsletter?



Q3 2025

Message from the President

Dear Florida Pharmacists,

It is both a privilege and a pivotal moment to speak with you as the President of FSHP. Floridians draw resilience from their environment, enduring both tranquil coasts and fierce storms, and rebuilding with renewed strength.

Florida's history proves our resilience. Challenges come, but with preparation, teamwork, and courage, we overcome them. Like communities rebuilding after storms, our profession must adapt and move forward together as a unified profession.

Today, the time is now to say YES! Yes, to advancing our profession. Yes, to standing side by side with our healthcare partners. And yes, to ensure that every decision begins and ends with what matters most: our patients.

Policy matters when it enhances care. Advocacy should guarantee universal access to safe, effective, and compassionate health services, regardless of location or insurance status. We advocate through meaningful data demonstrating success via outcomes, savings, and improved therapies. Our story must be told clearly and backed by evidence.

Pharmacy plays a vital role in healthcare. Our future depends on collaboration with physicians, nurses, and the entire team to ensure quality patient care because it is a collective commitment. Working together removes barriers, improves outcomes and patients receive the care they deserve. We also must shine a light on the work done quietly and daily to save lives and prevent adverse effects.

Thriving involves openness and leadership. Pharmacists play a role in advancing innovation, contributing to the development of AI and technology by applying their knowledge to support safe, effective, and patient-centered care.

We must recognize and promote pharmacists, technicians, residents, and students who are driving change in care. Their vision demonstrates the value of uniting expertise, empathy, and innovation, and sharing their stories highlights their impact on the profession and public.



Message from the President

My vision for FSHP is clear:

- Keep patients at the center of everything we do.
- Strengthen our partnerships to build a safer, more resilient healthcare system.
- Prepare for tomorrow by leading in technology, data, and innovation
- Empower every member of our profession to lead with courage, clarity, and compassion.

We are shaping Florida's healthcare future. Stakeholders are attentive and our patients are counting on us. The time is now to say yes and to act. Together, we will succeed. And together, we will.

We are actively contributing to the evolution of healthcare in Florida. All stakeholders remain engaged, and our patients rely on us for thoughtful action. Now is the moment to commit, to say yes, and move forward. Through collaboration, we will achieve success. This is an important moment for decision-making, and collaborative efforts will shape outcomes.

With gratitude and determination,

Madeline Camejo, PharmD, BCACP
President, Florida Society of Health-System Pharmacists

CLINICAL PEARL

Reaffirming TMP-SMX as First-Line Prophylaxis for *Pneumocystis jirovecii* pneumonia and *Toxoplasma* in Oncology Patient

Lee Amaya, PharmD, BCIDP

Patients with hematologic malignancies and recipients of hematopoietic stem cell transplantation (HSCT) face significant risk for opportunistic infections, particularly *Pneumocystis jirovecii* pneumonia (PJP) and *Toxoplasma gondii* reactivation. Guidelines tailored to oncology populations, including the National Comprehensive Cancer Network (NCCN), the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO), and the European Conference on Infections in Leukaemia (ECIL), consistently recommend trimethoprim-sulfamethoxazole (TMP-SMX) as the first-line prophylactic agent to protect against PJP and *Toxoplasma*.¹⁻⁵ Despite this, concerns about toxicity and allergy labels often lead to use of less effective alternatives. The objective of this article is to review the available data for the use of TMP-SMX in the prevention of PJP and *Toxoplasma*.

The Efficacy of TMP-SMX

For PJP, a Cochrane review by Stern et al. pooled data from 13 randomized trials consisting of non-HIV immunocompromised patients, including adult patients with acute leukemia, autologous HSCT recipients, solid organ transplant recipients and pediatric patients with acute lymphoblastic leukemia.⁶ The authors found an 85 percent reduction in PJP incidence and an 83 percent reduction in PJP-related mortality, with a number needed to treat of 19. Importantly, there was no significant increase in severe adverse events compared to placebo, and both daily and thrice-weekly dosing were effective.

For *Toxoplasma gondii*, the guidelines from the ECIL, 2022 recommend TMP-SMX as first-line prophylaxis in seropositive allogeneic-HSCT recipients, with either single-strength (SS) 80/400 mg daily or double-strength (DS) 160/800 mg three times weekly dosing.⁵ Malek et al. reported outcomes from a large single-center allogeneic-HSCT cohort: 7 percent of seropositive patients experienced *Toxoplasma* reactivation, 91 percent of whom had not received prophylaxis.⁷ TMP-SMX prophylaxis was associated with markedly improved outcomes, with median overall survival of 84.9 months compared to 17.2 months without prophylaxis.

In addition to PJP and *Toxoplasma*, TMP-SMX offers coverage against *Nocardia*, *Stenotrophomonas*, and other bacterial pathogens, providing broader benefit than alternative prophylactic options.

CLINICAL PEARL

Tolerability and Adverse Effects

Adverse events such as rash, electrolyte abnormalities, and cytopenias are well described but largely dose dependent and reversible. Single-strength daily dosing balances efficacy and tolerability in most oncology patients. Drug-induced immune thrombocytopenia (DITP) is uncommon and typically resolves with discontinuation. Reviews of antimicrobial-induced thrombocytopenia list TMP-SMX as a possible but rare trigger.^{8,9}

Re-challenge after mild reactions is often successful. Smibert et al. described a multicenter re-challenge program in immunocompromised patients, where 89 percent of participants tolerated TMP-SMX re-initiation without serious sequelae.¹⁰ This provides a practical framework for oncology and transplant centers facing high rates of TMP-SMX substitution.

Concerns about myelosuppression are based largely on observational data and do not establish causality. Risk appears higher in immunodeficient or geriatric patients, at higher doses, or with prolonged exposure.

Safety of TMP-SMX Including at Treatment Doses

Safety data extend into higher-dose exposures. Gaffney et al. examined double-strength TMP-SMX twice daily for bacterial prophylaxis in allogeneic-HSCT recipients during the peri-transplant period and found no delay in engraftment or increase in ICU transfer or mortality, though hyperkalemia was more frequent.¹¹

Dose optimization studies also support safety at the lower end. Haseeb et al. demonstrated that low-dose regimens for PJP treatment were as effective as higher doses but caused fewer adverse events.¹² Huang et al. evaluated low-dose prophylaxis in HIV-uninfected immunocompromised patients and found regimens of 160/800 mg or less three times weekly preserved efficacy while reducing cytopenias and renal toxicity.¹³

Masaki et al. performed one of the largest meta-analyses to date, across 2,808 patients, and found intermittent dosing provided similar efficacy but with significantly fewer discontinuations due to adverse events (risk ratio 0.51).¹⁴ Together these data show that TMP-SMX is safe across a range of doses, including at treatment intensities, while supporting SS daily dosing as a balance for prophylaxis.

CLINICAL PEARL

Allergy Labels and Missed Opportunities

TMP-SMX allergy labels are a persistent barrier to appropriate prophylaxis. A review by Lee et al. found many labels were vague or inconsistent with true hypersensitivity, and patients with these labels were significantly less likely to receive guideline-concordant prophylaxis.¹⁵ They were also more likely to receive less favorable alternatives. Allergy evaluation and de-labeling initiatives, along with re-challenge pathways, can restore access to TMP-SMX for many patients.

Alternatives and Their Limitations

When TMP-SMX cannot be used, alternatives listed in Table 1 are available but come with limitations. Atovaquone absorption is variable (especially with fasting), it can cause gastrointestinal (GI) upset, and its cost is high. Dapsone requires glucose-6-phosphate-dehydrogenase deficiency (G6PD) testing and offers no *Toxoplasma* coverage. Inhaled pentamidine protects only the lungs, leaving patients vulnerable to systemic and cerebral infection. Intravenous (IV) pentamidine requires monthly infusions, only protects against PJP, and has unique toxicities like nephrotoxicity, pancreatitis, and infusion reactions. These agents should be reserved for true intolerance since they offer reduced spectrum compared with TMP-SMX and have logistical, efficacy, or cost tradeoffs.

Clinical Takeaways for Pharmacists

TMP-SMX is the guideline-endorsed first-line prophylactic agent for both PJP and *Toxoplasma* in oncology patients. Single-strength daily dosing provides strong efficacy and tolerability. Adverse effects are usually dose dependent and reversible, and re-challenge is often successful. Pharmacists can support optimal use by standardizing TMP-SMX dosing, promoting allergy de-labeling and re-challenge when safe, and reducing reliance on less effective alternatives.

***Disclaimer:**

This article was developed with the assistance of artificial intelligence (AI) tools to support writing and synthesis of published literature. Dr. Amaya has reviewed, edited, and verified the content to the best of his ability to ensure accuracy and clinical relevance. Any errors or omissions are his own. Readers are encouraged to consult the original references and clinical guidelines when applying this information to patient care.

CLINICAL PEARL

Table 1. Comparison of Available Agents for PJP and Toxoplasma Prophylaxis

Agent	PJP Efficacy (Relative)	Toxoplasma Activity	Typical Prophylactic Dosing (Oncology/HSCT)	Key Limitations and Monitoring	Cost / Availability	Typical Use Case
TMP-SMX (trimethoprim-sulfamethoxazole)	Highest; best evidence for prevention and mortality reduction	Yes	Single-strength 80/400 mg PO daily (common); alternative: DS 160/800 mg TIW	AEs: rash, GI, hyperkalemia, renal dysfunction, cytopenias; rare DITP. Monitor CBC and BMP at baseline and periodically. Re-challenge often possible after mild reactions	Low cost; widely available	First-line for PJP and Toxoplasma prophylaxis when tolerated
Atovaquone	Moderate	Yes	1,500 mg PO daily with a high-fat meal (oral suspension)	Variable absorption requiring high-fat meal; costly; limited comparative outcome data; may require adherence support	High cost; formulary variability	Use when TMP-SMX is contraindicated or not tolerated and systemic coverage for Toxoplasma is desired
Dapsone	Moderate	No	100 mg PO daily	Requires G6PD testing; risk of hemolysis and methemoglobinemia; fewer data for oncology HSCT populations	Low cost; widely available	Use when TMP-SMX contraindicated and G6PD is normal; not appropriate when Toxoplasma prophylaxis is required

CLINICAL PEARL

Agent	PJP Efficacy (Relative)	Toxoplasma Activity	Typical Prophylactic Dosing (Oncology/H SCT)	Key Limitations and Monitoring	Cost / Availability	Typical Use Case
Inhaled pentamidine	Effective for pulmonary PJP only	No	300 mg via nebulizer once monthly	Protects only lungs; no systemic or CNS protection; requires nebulizer setup; bronchospasm risk; logistical challenges	Moderate cost; operational complexity	Use when systemic agents cannot be used and pulmonary-only protection is acceptable
Intravenous pentamidine	Moderate	No	4 mg/kg (maximum 300 mg) IV once every 4 weeks	Infusion reactions, nephrotoxicity, pancreatitis, limited coverage	Moderate cost	Use when patient cannot tolerate or has contraindications to oral prophylaxis; not appropriate when Toxoplasma prophylaxis is required

References:

- National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections. (Version 1.2025). Retrieved September 16, 2025, from https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
- Christopeit, M., Schmidt-Hieber, M., Sprute, R., Buchheidt, D., Hentrich, M., Karthaus, M., Penack, O., Ruhnke, M., Weissing, F., Cornely, O. A., & Maschmeyer, G. (2021). Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). *Annals of hematology*, 100(2), 321–336. <https://doi.org/10.1007/s00277-020-04297-8>
- Classen, A. Y., Henze, L., von Lilienfeld-Toal, M., Maschmeyer, G., Sandherr, M., Graeff, L. D., Alakel, N., Christopeit, M., Krause, S. W., Mayer, K., Neumann, S., Cornely, O. A., Penack, O., Weisinger, F., Wolf, H. H., & Vehreschild, J. J. (2021). Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO). *Annals of hematology*, 100(6), 1603–1620. <https://doi.org/10.1007/s00277-021-04452-9>
- Maertens, J., Cesaro, S., Maschmeyer, G., Einsele, H., Donnelly, J. P., Alario, A., Hauser, P. M., Lagrou, K., Melchers, W. J., Helweg-Larsen, J., Matos, O., Bretagne, S., Cordonnier, C., & 5th European Conference on Infections in Leukaemia (ECIL-5), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organisation for Research and Treatment of Cancer (EORTC), the Immunocompromised Host Society (IHS) and the European LeukemiaNet (ELN) (2016). ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. *The Journal of antimicrobial chemotherapy*, 71(9), 2397–2404. <https://doi.org/10.1093/jac/dkw157>
- Aerts, R., Mehra, V., Groll, A. H., Martino, R., Lagrou, K., Robin, C., Perruccio, K., Blijlevens, N., Nucci, M., Slavin, M., Bretagne, S., Cordonnier, C., & European Conference on Infections in Leukaemia group (2024). Guidelines for the management of Toxoplasma gondii infection and disease in patients with haematological malignancies and after haematopoietic stem-cell transplantation: guidelines from the 9th European Conference on Infections in Leukaemia, 2022. *The Lancet. Infectious diseases*, 24(5), e291–e306. [https://doi.org/10.1016/S1473-3099\(23\)00495-4](https://doi.org/10.1016/S1473-3099(23)00495-4)
- Stern, A., Green, H., Paul, M., Vidal, L., & Leibovici, L. (2014). Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. *The Cochrane database of systematic reviews*, 2014(10), CD005590. <https://doi.org/10.1002/14651858.CD005590.pub3>
- Malek, A. E., Al-Juhaishi, T., Milton, D. R., Ramdial, J. L., Daher, M., Olson, A. L., Srour, S. A., Alatrash, G., Oran, B., Mehta, R. S., Khouri, I. F., Bashir, Q., Shah, N., Ciurea, S. O., Rondon, G., Maadani, F., Hosing, C., Marin, D., Kebriaei, P., Rezvani, K., ... Ahmed, S. (2024). Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. *Bone marrow transplantation*, 59(5), 699–704. <https://doi.org/10.1038/s41409-024-02238-x>
- Wayne, C., Guéry, E. A., Rollin, J., Baglo, T., Petermann, R., & Gruel, Y. (2020). Pathophysiology and Diagnosis of Drug-Induced Immune Thrombocytopenia. *Journal of clinical medicine*, 9(7), 2212. <https://doi.org/10.3390/jcm9072212>
- Loo, A. S., Gerzenshtein, L., & Ison, M. G. (2012). Antimicrobial drug-induced thrombocytopenia: a review of the literature. *Seminars in thrombosis and hemostasis*, 38(8), 818–829. <https://doi.org/10.1055/s-0032-1328882>
- Smitbert, O., Urbancic, K., Douglas, A., Devchand, M., Slavin, M., & Trubiano, J. (2018). 1578. Back to Bactrim—Utilizing Preferred Prophylaxis Strategies in Immunocompromised Hosts Via a Trimethoprim-Sulfamethoxazole Rechallenge Program. *Open Forum Infectious Diseases*, 5(Suppl 1), S493. <https://doi.org/10.1093/ofid/ofy210.1406>
- Gaffney, K. J., Urban, T. A., Lucena, M., Rybicki, L., Majhail, N. S., & Mossad, S. B. (2023). Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period. *Clinical hematology international*, 5(2-3), 65–70. <https://doi.org/10.1007/s44228-023-00029-7>
- Haseeb, A., Abourehab, M. A. S., Almallik, W. A., Almontashri, A. M., Bajawi, S. A., Aljoaid, A. M., Alshahabi, B. M., Algethamy, M., AlQarni, A., Iqbal, M. S., Mutlaq, A., Alghamdi, S., Elrggal, M. E., Saleem, Z., Radwan, R. M., Mahrous, A. J., & Faidah, H. S. (2022). Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review. *International journal of environmental research and public health*, 19(5), 2833. <https://doi.org/10.3390/ijerph19052833>
- Huang, H. B., Shi, J. H., Hu, Y. G., Zhu, Y. B., & Yu, D. X. (2025). Low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis jirovecii pneumonia in HIV-uninfected patients: a systematic review and meta-analysis. *Frontiers in pharmacology*, 16, 1545436. <https://doi.org/10.3389/fphar.2025.1545436>
- Masaki, T., Ishikawa, K., Fujino, T., Koyamada, R., Kawai, F., Ota, E., & Mori, S. (2024). Intermittent Versus Daily Trimethoprim/Sulfamethoxazole Regimens for Pneumocystis Pneumonia Prophylaxis: A Systematic Review and Meta-analysis. *Open forum infectious diseases*, 11(9), ofae499. <https://doi.org/10.1093/ofid/ofae499>
- Lee, W. I., Lam, L., Bacchi, S., Jiang, M., Inglis, J. M., Smith, W., & Hissaria, P. (2024). Antibiotic prophylaxis in immunosuppressed patients - Missed opportunities from trimethoprim-sulfamethoxazole allergy label. *The World Allergy Organization journal*, 17(1), 100856. <https://doi.org/10.1016/j.waigjou.2023.100856>

SPECIAL INSIGHTS

IRA Updates and Covered Entities Implications

With the Inflation Reduction Act (IRA) set to roll out January 2026, uncertainties remain regarding the platform drug manufacturers will utilize to exchange data with 340B covered entities.

The IRA was established with the intention of providing financial assistance to those enrolled in a Medicare program. The program authorizes the Secretary of Health and Human Services to negotiate prices with manufacturers for certain single-source chemical drugs and biological products under Medicare part B (physician-administered drugs) or part D (retail prescription drugs). The IRA will start with Medicare part D in 2026 and will expand to Medicare part B in 2028. The negotiated prices are subject to a ceiling price, known as the maximum fair price (MFP). The roll-out of the program will include 10 medications, manufactured by ten different drug manufacturers. Together, these drugs accounted for \$50B billion or 20% of gross Medicare part D drug costs from June 2022 through May 2023. There are an additional 15 drugs that will be added into the program starting in 2027.

IRA Selected Medications, 2026	IRA Selected Medications, 2027	
Eliquis	Austedo	Ozempic; Rybelsus; Wegovy
Enbrel	Breo Ellipta	Pomalyst
Entresto	Calquence	Tradjenta
Farxiga	Ibrance	Trelegy Ellipta
Imbruvia	Janumet	Vraylar
Januvia	Linzess	Xifaxan
Jardiance	Ofev	Xtandi
Novolog; Fiasp	Otezla	
Stelara		
Xarelto		

SPECIAL INSIGHTS

Dispensing entities and drug manufacturers who want to participate in the IRA program must register in the Medicare Transaction Facilitator (MTF). The MTF is composed of 2 modules: the MTF Data Module (MTF DM) and the MTF Payment Module (MTF PM). The MTF will coordinate refund payments from pharmaceutical manufacturers to dispensing entities.

Centers for Medicare & Medicaid Services (CMS) will utilize National Council for Prescription Drug Programs (NCPDP) data to identify and validate initial dispensing entity users. The entity's point of contact (authorizing official) is then required to register in the portal, designating others that can attest to, upload, and view data and information that will be exchanged between covered entities and drug manufacturers. At this time, the data required from covered entities (CEs) is limited, but there is potential for manufacturers to request more details. Manufacturers have expressed concern that, without a standardized point-of-sale mechanism to identify 340B claims, widespread duplicate discounts will occur.

Manufacturers may choose to use the MTF PM to issue refund payments to dispensing entities that acquire selected drugs above the MFP. If a manufacturer does not use the MTF PM, they are still required to transmit payment information through the MTF DM and issue refunds via their own payment mechanism. In either case, pharmacies will have visibility into the manufacturer's effectuation plan, including whether the manufacturer has opted to use the MTF PM and how refunds will be processed. In a new notice to covered entities, CMS announced that the initial ten manufacturers signaled their intent to use the MTF payment module.

Under the IRA, if an MFP-eligible drug is also 340B-eligible, the manufacturer must make the drug available at the point of service at the lesser of the 340B ceiling price or the MFP.

With the establishment of the Medicare Drug Price Negotiation Program (MDPNP), there is a section that discusses a new 340B Rebate Model Pilot Program. With a rebate program, the purchasing of drugs will shift, from purchasing at a 340B price, to purchasing at a wholesale acquisition cost (WAC) price and then waiting approximately 10 days for a refund from a drug manufacturer. There are concerns regarding the platform manufacturers will use to review and share data with 340B covered entities. Platforms such as Kalderos, Beacon, among others, and have been mentioned. With the rebate program set to roll out in January 2026, the requirements on covered entities are still pending including staffing needs to submit the data requested, and what platform(s) will the manufacturers use. In addition to waiting for rebate payments, CEs will potentially need additional staff to meet the submission requirements the rebate program will mandate.

SPECIAL INSIGHTS

CEs are entering a period of significant uncertainty, bracing for impacts from both the IRA and potential manufacturer rebates. Impacts such as reimbursement at the average wholesale price (AWP) instead of WAC, rebates not being paid in a timely manner to covered entities, and how patient data will be used. Moreover, the IRA presents with challenges to 340B program such as how to exclude 340B drugs from rebates which apply to part D claims beginning January 1, 2026, and how the requirement to offer MFP on the newly negotiated prices will work with 340B operationally.

PhRMA's "Meet Mark ad"

There is yet another campaign from Pharmaceutical Research and Manufacturers of America (PhRMA) called "Meet Mark" about how 340B covered entities deny patient discounts and keep the manufacturer cost savings for themselves. The 340B program was created to provide overall cost savings for federally qualified health centers (FQHCs) and sexually transmitted disease (STD) clinics, health systems, and other facilities that service indigent and under-funded patients. The 340B drug pricing program is a federal law, which per HRSA, enables covered entities to "stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services". The intent of the program was never to give the cost savings on one drug directly back to one patient. What is often overlooked is that organizations that service underfunded patients must have support programs in place to ensure patients get medications at no cost, or via a sliding scale based on income. Organizations that receive cost savings from the 340B program can transparently share several ways they use the funds such as creating clinics in healthcare deserts, starting new programs for their community to ensure transportation to healthcare services, and new equipment to better care for patients that they wouldn't be able to afford had not it be for the cost savings.

Summary

The 340B program is a federal program established over 30 years ago that should continue to support our communities and health care systems, particularly those that are in rural areas that will not survive without the cost savings they have relied upon. Significant changes in the operational workflow of CEs and pharmacies are on the horizon due to the IRA and potential manufacturer rebate programs. Thus, early preparation and awareness are critical. To stay informed, pharmacies should regularly visit the CMS Drug Price Negotiation Program webpage and subscribe to Medicare Transaction Facilitator updates. There is a need for 340B covered entities and stakeholders to prepare for this upcoming change by staying up to date with congressional dynamics, agencies statements, comments and resolution as the year ends.

SPECIAL INSIGHTS

References:

1. Centers for Medicare & Medicaid Services. Manufacturer Technical FAQs. Published August 2023. Accessed August 20, 2025. <https://www.cms.gov/files/document/manufacturer-technical-faqs.pdf>
2. Centers for Medicare & Medicaid Services. Pharmacy and Dispensing Entity Medicare Transaction Facilitator Fact Sheet. Published August 2023. Accessed August 20, 2025. <https://www.cms.gov/files/document/pharmacy-and-dispensing-entity-mtf-fact-sheet.pdf>
3. Centers for Medicare & Medicaid Services (CMS). Pharmacy and Dispensing Entity MTF FAQ. Published August 2023. Accessed August 20, 2025. <https://www.cms.gov/files/document/pharmacy-and-dispensing-entity-mtf-faq.pdf>
4. Health Resources and Services Administration. 340B Model Pilot Program. HRSA.gov. Accessed August 22, 2025. <https://www.hrsa.gov/opa/340b-model-pilot-program>
5. Kirkwood C. Preparing for the Medicare Transaction Facilitator. Pharmacy Times. Published August 30, 2023. Accessed September 8, 2025. <https://www.pharmacytimes.com/view/preparing-for-the-medicare-transaction-facilitator>
6. Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly. Federal Register. 42 CFR Parts 417, 422, 423, 460. April 15, 2025. Accessed August 27, 2025. <https://www.federalregister.gov/documents/2025/04/15/2025-06008/medicare-and-medicaid-programs-contract-year-2026-policy-and-technical-changes-to-the-medicare>
7. Pharmacy and Dispensing Entity Resources. Centers for Medicare & Medicaid Services. Updated July 29, 2025. Accessed August 27, 2025. <https://www.cms.gov/priorities/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/pharmacy-and-dispensing-entity-resources>
8. Pharmaceutical Research and Manufacturers of America (PhRMA). New “Meet Mark” Ad Exposes How the 340B Hospital Markup Program Drives Up Costs for Everyone. PhRMA. Published August 29, 2023. Accessed September 8, 2025. <https://phrma.org/blog/new-meet-mark-ad-exposes-how-the-340b-hospital-markup-program-drives-up-costs-for-everyone>

FSHP COMPONENT UPDATES

We are proud to showcase the 2025 - 2026 FSHP
Components and their respective leaders!

**Ambulatory Care
Clinical Forum**

Chair: Heather Randles
Vice Chair: Rakhi Patel
Immediate Past Chair: Francheska Marte

Provides a mechanism for Florida pharmacists within a specialty area to network, share best practices, discuss key hot topics in ambulatory care, and works on various educational or resource tools.

**Communications
Council**

Chair: Beatriz Jimenez Cadilla
Vice-Chair: Claudia Lopez
Immediate Past Chair: Eduardo Martinez Sanchez

Oversees the various methods of how the organization provides information and content to the membership (i.e., website, organization newsletter, social media, educational videos).

**Educational
Affairs Council**

Chair: Cher Enderby
Vice Chair: Jessica Andrews
Immediate Past Chair: Angelica Berni

Plans, executes, and evaluates educational programming for pharmacy professionals through meetings, conferences, webinars, and other educational forums.

**Legal &
Regulatory
Affairs Council**

Chair: Kathy Baldwin
Vice-Chair: Kenneth Komorny
Immediate Past Chair: Mark Mikhael

Actively reviews state & federal legislative issues affecting the practice of pharmacy and maintains a contact system with key officials; represents FSHP and is available as a resource as necessary at Florida Board of Pharmacy meetings.

**Membership
Affairs Council**

Chair: Joseph Mendes
Vice-Chair: Sanil Kanjookaran
Immediate Past Chair: Jessica Lendoiro

Plans membership development and implements recruitment and retention programs; provides input to the FSHP Board of Directors for pharmacist, new practitioner, resident, technician and student member relations and makes recommendations for future involvement for FSHP members.

FSHP COMPONENT UPDATES

**Professional
Affairs Council**

Chair: Tara Higgins
Vice-Chair: Chloe Gernhard
Immediate Past Chair: Lisa Thames

Assists with developing and maintaining the FSHP Administrative & Professional Policies & Procedures Manual; ensures that membership is abreast of current information regarding the Society and the profession of pharmacy; collaborates with staff regarding member communication via the newsletter, website, email and Social Media; serves as selection committee for awards recipients; coordinates the FSHP Poster Session and assists with Regional Society involvement within the Society.

**Technician
Affairs Council**

Chair: Darren Davis, BA,CPHT,RPhT
Vice-Chair: Crystal Lipko
Immediate Past Chair: Elizabeth Lewallen,CPHT

Provides input to the FSHP Board of Directors on technician involvement regarding education, communication, and legislative issues, and makes recommendations for future involvement for technician members.

**Emergency
Medicine/Critical
Care Clinical
Forum**

Chair: Lauren Koscal
Vice-Chair: Cheryl Wood
Immediate Past Chair: Danielle Padgett

Provides a mechanism for Florida pharmacists practicing in acute care areas (emergency medicine, critical care, toxicology, trauma) to network, share best practices, discuss key hot topics within acute care areas, and work on various educational or resource tools.

**Medication
Safety Clinical
Forum**

Chair: Stacy Carson
Vice-Chair: Heather Upchurch
Immediate Past Chair: Heather Petrie

A Forum where Florida pharmacists with a passion for medication safety can network, share best practices, collect and evaluate healthcare related medication errors and risks, strategize solutions to mitigate future medication errors in health-systems, and collaborate on various educational or resource tools.

Want to nominate a member for the next newsletter spotlight?

Fill out the nomination form!



REGIONAL SOCIETY UPDATE

Capital Society of Health-System Pharmacists

Regional Officers



Vacant

President



Joan
Hazen

Treasurer



Jill
Green

Secretary



Jay
Wallace

CE Coordinator

The Capital chapter was started by Mike McQuone in the late 1980's when he saw an unmet need for a chapter in the state Capital and big bend region. We have worked to provide forums for local hospital pharmacists and technicians to gather, obtain independent live continuing education, and have representation at the state organization. We have maintained representatives on the Legal and Regulatory Affairs Council nearly every year of our existence. We have always been small, counting on a core group of officers as well as some local speakers who have visited our meetings multiple times to share their wisdom. Some names that have come to mind include Michael Jackson, Phillip Treadwell, and Soheyla Mahdavian. We are expecting to provide a live program in late October with a psych/neuro focus. Creating a succession plan is a high priority, as we have relied on a small group of officers reprising their roles year in and year out.

Aside from chapter related activities, I would like to focus on some recent member successes. The bulk of our membership comes from Tallahassee Memorial Hospital which continues to expand. One example is the expansion of pharmacy residency programs in the last couple years. FSHP members Natalie Robertson, Kelly Rodrigue, and Ryan Johnson have spearheaded growth from 3 PGY1 residency positions to add a combined PGY1/PGY2 HSPAL (Health-System Pharmacy Administration and Leadership) slot as well as a PGY2 Emergency Medicine Pharmacy residency. Dr. Robertson, Assistant Director for Clinical Services (and recent volunteer for CSHP Secretary), had been Residency Program Director from 2004 to 2022 for the PGY1 program and is the RPD for the HSPAL residency. Dr. Rodrigue, our Infectious Disease Clinical Pharmacist, has taken the reins as RPD for the PGY1 program since 2022. Dr. Johnson is an Emergency Medicine clinical pharmacist, an Assistance Professor at Florida A&M University and serves as RPD for the PGY2 Emergency Medicine Pharmacy residency. He received his residency certificate in 2018 from TMH. It is a pleasure to work with such bright leaders as well as the many leaders of tomorrow that develop through the program. We hope upcoming graduates keep us in mind when planning their residency applications.

REGIONAL SOCIETY UPDATE

Central Florida Society of Health-System Pharmacists

Regional Officers



Sydney McNeill
President



Leslie Wooten
Immediate Past President



Caitlin Thomas
President-Elect



Leila Becirevic
CE Coordinator



Melanie Perry
Treasurer




Aaron Effoe
Secretary



Abbi Rowe
Marketing Coordinator

This year we've been able to host several great CE presentations and mixer events in the central FL area and are excited for the Fall events that are already underway. This year, we had a great CE presentation on updates in hyperlipidemia management at Bulla Gastrobar, a PAC Fundraiser at Seasons 52, volunteering at Ronald McDonald House in conjunction with the student chapter, resident mixer at Primrose Lanes, and great representation at the FSHP House of Delegates during the 2025 annual meeting.



Follow us on social media for more up-to-date information on our upcoming events:

X: @CFSHPOffical

Instagram: @cfshpofficial

Facebook: Central Florida Society of Health-System Pharmacists

REGIONAL SOCIETY UPDATE

Central Florida Society of Health-System Pharmacists

Regional Officers



Sydney McNeill
President



Leslie Wooten
Immediate Past President



Caitlin Thomas
President-Elect



Leila Becirevic
CE Coordinator



Melanie Perry
Treasurer



Aaron Effoe
Secretary



Abbi Rowe
Marketing Coordinator

We are excited for our next sponsored CE dinner October 8th on “Navigating Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Syndrome.” A sponsored dinner is also being planned with the student chapter in November. Planning for Spring 2026 is continuing with plans to do our specialty CE in March with a 2-hour medication error board-approved presentation. We plan to host more sponsored-dinner CE events in the Spring as well.

We are looking forward to the remainder of this year and to another successful year in 2026!



Follow us on social media for more up-to-date information on our upcoming events:

X: @CFSHPOffical

Instagram: @cfshpofficial

Facebook: Central Florida Society of Health-System Pharmacists

REGIONAL SOCIETY UPDATE

Southwest Society of Health-System Pharmacists

Regional Officers



Les Louden
President



Matthew Antonopoulos
President-Elect



Joby Palathinkal
Immediate Past President



Melissa Ruble
Treasurer



Christine Tabulov
CE Coordinator



Shawn Huss
CE Coordinator



Dante Kazerounian
Board Member



Veldana Alliu
Board Member



Mitch Purse
Board Member

The Southwest Florida Regional Society continues to thrive in 2025, with exciting milestones and impactful programming that reflect our members' dedication to advancing health-system pharmacy.

We are proud to share that SWFSHP was honored as the 2025 Distinguished Regional Society at the FSHP Annual Meeting. This recognition is a testament to the collective efforts of our members and leadership team. Thank you to everyone who contributed to this achievement, your commitment and collaboration made this possible!

In conjunction with the FSHP Annual Meeting, we hosted our 2nd Annual SWFSHP Regional Social Event at the High Velocity Bar's Upper Deck within the Orlando World Marriott Center. This gathering offered a fantastic opportunity for regional members to connect, celebrate, and recharge. We're grateful to all who attended and especially those who participated in the FSHP House of Delegates—your engagement helps shape the future of our profession.

REGIONAL SOCIETY UPDATE

As the year progresses, we remain focused on delivering high-quality continuing education and meaningful networking opportunities:

- Virtual Medication Safety CE returns by popular demand on August 26th from 1–3 PM, just in time for pharmacists seeking last-minute CE credits before the September renewal deadline. The session will be led by Carrie D’Aiuto and Annie Alexis from BayCare Health System, offering practical strategies to reduce medication errors.
- We continue to support the Tampa Bay Residency Forum (TBRF), which will host a Virtual Pharmacy Week Preceptor Development Event on Wednesday, October 22nd at 1 PM via Zoom or Teams. This initiative fosters growth and mentorship among preceptors and residents in our region.
- Our leadership team is expanding to better serve our members and support future initiatives. We’re excited to welcome:
 - Shawn Huss who has been serving as an additional Education Coordinator, a role designed to enhance training continuity and CE success.
 - Erika Mooney as Liaison to the Education Coordinators, providing added support for event planning and CE logistics.
 - Priya Leary as Co-Liaison to the Tampa Bay Residency Forum, strengthening coordination and development opportunities for pharmacy residents.

As we welcome new leaders, we also want to express our heartfelt appreciation to Chrissy Tabulov, who will be completing her term as Secretary/Continuing Education Coordinator this year. Chrissy has played a critical role in the success of our CE programming, and we are deeply grateful for her dedication, leadership, and many contributions to SWFSHP.

With strong momentum and a growing team, we invite all members to stay engaged as we continue building a vibrant, connected pharmacy community in Southwest Florida.

Best regards,
Les Loudon
SWFSHP President

REGIONAL SOCIETY UPDATE



STUDENT CHAPTER UPDATE

University of Florida College of Pharmacy- Lake Nona Campus

Our SSHP chapter had an exciting year filled with engaging events, increased turnout, and valuable networking opportunities! Beginning in November 2024, our student chapter, along with the dedicated residency showcase committee, hosted its in-person as well as virtual residency showcase—an incredible event for networking and learning more about residency programs from residency directors and current residents.



STUDENT CHAPTER UPDATE

Throughout the year, our chapter hosted volunteer events at the Ronald McDonald House to cook meals for families staying at the Ronald McDonald House at Nemours Children's Hospital. The current CFSHP president and past president helped volunteer at one of these events!

This past February, our chapter held an interactive code cart wars GBM. Attendees learned from an emergency department residency director and then put their knowledge to the test by assembling a mock code cart against the clock!



STUDENT CHAPTER UPDATE

During the summer, SSHP collaborated with Pedigator, UF's pediatric organization, as a part of the summer volunteer program with Camp Boggy Creek on the medical team, working alongside nurses to assist campers on check-in day.

Just this September, our chapter held its annual hospital intern panel. Current students working in the healthcare setting shared their experiences and eagerly answered and tackled questions with enthusiasm!



Follow us on social media for more updates on our student chapter:

Instagram: @sshpuforlando

STUDENT CHAPTER UPDATE

University of South Florida- Taneja College of Pharmacy

The Student Society of Health-System Pharmacy (SSHP) chapter at the University of South Florida (USF) Taneja College of Pharmacy (TCOP) has stayed very active over the past 18 months. Members have focused on promoting the profession of pharmacy while also supporting one another in their professional journeys. The chapter has provided many opportunities for students to learn more about careers in health-system pharmacy and to develop the skills they will need as future pharmacists.

One way SSHP has supported student development is through career preparation events. The chapter held an Internship Panel where current pharmacy interns in the Tampa Bay area shared their experiences and gave advice to first- and second-year students who are preparing to apply for internships themselves. A Postgraduate Training Informational Session also gave students the chance to hear directly from the Director of Postgraduate Programs at TCOP about residency and fellowship opportunities. Many members also participated in a Residency Preparation Webinar series hosted in collaboration with Tampa General Hospital residents and pharmacists, which gave them valuable insights on CV building, interviewing, and the residency match process. Another highlight was the annual Clinical Skills Competition, which challenges third- and fourth-year students to apply their pharmaceutical knowledge to real-world cases. The winning student earned registration to attend the ASHP Midyear Clinical Meeting, an experience that allows attendees to connect with students and professionals across the country.

Community service has also been a big part of the chapter's efforts. Twice a year, in April and October, SSHP organizes a Drug Take Back Day at the Morsani Center. This event is held in collaboration with the USF Police Department, the Hillsborough County Anti-Drug Alliance, and practicing pharmacists to give the public a safe place to dispose of unused medications. In addition to students volunteering during Drug Take Back Day, the chapter has participated in other projects, such as teaching families about medication safety at the Black Maternal Health Week community block party, as well as organizing a professional clothing and scrubs drive to provide these resources to fellow healthcare students.

STUDENT CHAPTER UPDATE

SSHP has also worked hard to create mentorship and networking opportunities for its members. The chapter hosted a mentorship dinner, where students were able to connect with faculty and practicing pharmacists in a more personal setting. SSHP also represented the organization at the Student Organization Showcase at TCOP to help new students learn about what SSHP has to offer and recruit new members. Partnerships with the Southwest Society of Health-System Pharmacists (SWFSHP) have also been very meaningful. Every year, two SSHP student leaders are awarded scholarships through this partnership. The relationship between SSHP and SWFSHP continues to make positive impacts with an upcoming Brown Bag Day event at HCA South Tampa Hospital on October 18, 2025. This event has been coordinated by the current SSHP President, Mollie Walters, and the current SWFSHP President-Elect, Dr. Matthew Antonopoulos.



Looking ahead, the chapter is excited to continue building on these experiences. The upcoming Drug Take Back Day on October 25, 2025, will once again bring together students, pharmacists, and community partners to make a positive impact on public health. SSHP at USF is proud of the work its members have done to support one another, give back to the community, and prepare for their future roles as pharmacists. By combining service, leadership, and professional development, the chapter continues to grow while representing the values of both FSHP and ASHP.

STUDENT CHAPTER UPDATE



Join Our Pharmacy Team for a Brown Bag Event*

Saturday, October 18, 2025

9 a.m. - 12 noon

HCA Florida South Tampa Hospital Auditorium

located in the Administration Building

2901 W. Swann Avenue

Tampa, FL 33609

Bring your current medications in a "brown bag" and learn about their common uses, side-effects, and interactions with other medications. **HCA Florida South Tampa Hospital** pharmacists and students from the **USF Taneja College of Pharmacy** will review what you're taking, make sure you're taking them correctly and answer any questions!

This includes:

- Prescription medications
- Over-the-counter medicines
- Herbal medicines
- Vitamins & supplements

*in collaboration with **South West Society of Health System Pharmacists**

To register, call 844-630-5295 or go to [HCAFloridaSouthTampaHospital/classesandevents](https://www.hcafloridasouthtampahospital.com/classesandevents)



NEU_MULTI_1028700_OG_2025

STUDENT CHAPTER UPDATE

2024 Scholarship Recipients Mo Zaed and Victoria Phan



Drug Take Back Day April 2025



Student Organization Showcase 2024



Professional Clothing and Scrubs Drive April 2025



Membership Dinner March 2024




STUDENT CHAPTER UPDATE

STUDENT SOCIETY OF HEALTH SYSTEM PHARMACISTS (SSHP)

UF College of Pharmacy, Jacksonville Campus

fall highlights!

Internship Panel



At our September General Body Meeting, the Jacksonville chapter of SSHP put on an internship panel aimed toward first-year pharmacy students interested in pursuing an intern position while they are in school. A panel of eight second and third-year students from a variety of fields including community, hospital, and compounding pharmacy spoke on where they worked, the details of their daily tasks, and the value they have found in their internship experience.

Also at this meeting, we were able to put on a raffle to refund one student the cost of their membership, in addition to sponsoring two fourth-year students to attend ASHP midyear!

Guest Speaker Dr. Jessica Andrews



At our August General Body Meeting, we had Dr. Jessica Andrews, the incoming NEFSHP President, as our first speaker. Dr. Andrews spoke to our students about her role as a Cardiac Critical Care Clinical Pharmacist and opportunities for shadowing and getting involved in upcoming NEFSHP events.

2025 FSHP AWARDS & SCHOLARSHIP WINNERS

Congratulations

Elevate

Anna Thiel Meritorious Service Award

Heather Petrie
PharmD, BCPS, MBA



Congratulations!

Elevate

FSHP Fellow Award

Kathleen Baldwin
PharmD, MS, BCPS, CPh



Congratulations!

Elevate

Dave Osterberger Excellence in Pharmacy Leadership Award

Dominick Curry
PharmD, BCCCP



Congratulations!

Elevate

FSHP Fellow Award

Lindsey Childs-Kean
PharmD, MPH, BCPS, FASHP



Congratulations!

Elevate

Distinguished Service Award

Kenneth Komorny
PharmD, BCPS



Congratulations!

Elevate

FSHP Fellow Award

Sara Panella
PharmD, BCPS, CPh



Congratulations!

2025 FSHP AWARDS & SCHOLARSHIP WINNERS

Elevate

Institutional Newsletter Award

Memorial Hospital Miramar Pharmacy Newsletter



Congratulations!

Elevate

Paul Magalian
Scholarship Recipients

Kelly Bishop
University of Florida - Gainesville

Britnee Innocent
University of South Florida

Eileen Velez Torres
Lake Erie College of Osteopathic Medicine



Congratulations!

Elevate

Institutional Newsletter Award

Memorial Hospital Miramar Pharmacy Newsletter



Congratulations!

Elevate

Pharmacist Forerunner Award

Oscar Santalo
PharmD, MBA, MHA, BCPS, CPh



Congratulations!

Elevate

Joe Salem Membership Recruiter & New Practitioner Recruiter of the Year Award

Glenn Graziose
BS Pharm, MBA



Congratulations!

Elevate

Pharmacist of the Year

Mark Mikhael
PharmD



Congratulations!

Elevate

Mentor of the Year Award

Tanya Nelson
PharmD



Congratulations!

Elevate

Pharmacy Technician Forerunner Award

Marscella Snead
RPhT



Congratulations!

2025 FSHP AWARDS & SCHOLARSHIP WINNERS

Elevate
Residency Preceptor
Of The Year
Barbara Santevecchi
PharmD, BCIDP



Congratulations!

Elevate
Student Chapter
of the Year Award
University of Florida
Gainesville



Congratulations!

Elevate
Award For Research In Pharmacy
Practice
Kimberly Tran
PharmD



Congratulations!

Elevate
Technician of the Year
Austin Kucher
CPHT



Congratulations!

Elevate
Distinguished Regional Society
of the Year Award
Southwest Society



Congratulations!

Elevate
Stuart Ulrich Service Scholarship
Caitlyn Frizzell
University of Florida - Gainesville
Andrew Pedroff
University of Florida - Jacksonville



Congratulations!

Congratulations

FSHP ANNUAL MEETING RECAP



FSHP ANNUAL MEETING RECAP



FSHP ANNUAL MEETING RECAP



FSHP ANNUAL MEETING RECAP



FSHP ANNUAL MEETING RECAP





**Check out the
Pharm So Hard podcast!**

LinkedIn

facebook

twitter

Instagram

@FSHPofficial

The FLORxIDA Times newsletter is published by the FSHP Communications Council.

Thank you to the following people for your contributions:

Beatriz Jimenez-Cadilla

Stacey Maravent

Tamekia Bennett

Daniella Abi Kheir

Lee Amaya

Rachel Ross

Viviana Alvarez Feliciano

Kevin Taylor

Madeline Camejo

*As always, a special thanks to the
councils liaisons and member submissions!*

Contact us to get your content in our next newsletter: fshp@fshp.org